- Home
- LANV vs ALXO Comparison
LANV vs ALXO Comparison
Compare LANV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LANV | ALXO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | 2066 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.9M | 205.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LANV | ALXO |
|---|---|---|
| Price | $1.21 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 12.8K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.51 |
| 52 Week High | $2.54 | $2.66 |
Technical Indicators
Market Signals| Indicator | LANV | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 53.04 |
| Support Level | $1.03 | $1.96 |
| Resistance Level | $1.79 | $2.31 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.00 | 28.43 |
Price Performance
Historical ComparisonAbout LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.